Treatment.com AI Inc. will roll out a new solution, AI Pharmacy Assistant, designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments. As one example, the Ontario government recently announced pharmacies… Continue reading TREATMENT.COM AI ANNOUNCES AI PHARMACY ASSISTANT

Merck reported strong second-quarter financial results, exceeding Wall Street’s expectations with revenue of $16.11 billion and adjusted earnings per share (EPS) of $2.28, compared to analyst estimates of $15.84 billion in revenue and $2.15 EPS. This performance was driven by robust sales from its leading cancer drug Keytruda, which generated $7.27 billion, a 16% increase… Continue reading Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda

Biovaxys Technology Corp. has closed the first tranche of its previously announced non-brokered private placement with the issuance of seven million units of the company at a price of five cents per unit for aggregate gross proceeds of $350,000, and the issuance of 14,672,000 shares at a deemed value of five cents per debt settlement… Continue reading BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announces that the U.S. Food and Drug Administration (FDA) has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. Alzheimer’s disease (AD) is a progressive brain disorder… Continue reading Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer’s Disease

VANCOUVER, BC, July 29, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform, is pleased to announce that it has executed a binding Letter of Intent (“Agreement”) with AP Visionaries, Inc. of Ontario (“APVI”) to jointly develop… Continue reading Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies

On Friday, Bristol Myers Squibb reported robust second-quarter earnings and revenue that exceeded Wall Street expectations, prompting the pharmaceutical giant to raise its full-year guidance. The company now forecasts a revenue increase at the “upper end” of the low single-digit range, up from its previous low single-digit growth estimate provided in April. Bristol Myers also… Continue reading Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

On Friday, European drug regulators rejected the Alzheimer’s treatment Leqembi, developed by Biogen and Eisai, presenting a significant setback for the companies as they attempt to increase the drug’s adoption in the U.S. The European Medicines Agency’s human medicines committee advised against granting marketing authorization for Leqembi, citing that its benefits in delaying cognitive decline… Continue reading European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai

Health authorities in Kerala, a southern Indian state, are on high alert following a recent outbreak of the deadly Nipah virus, which has led to the death of a 14-year-old boy. The state government is currently undertaking extensive contact tracing to monitor and test individuals who came into contact with the deceased boy. Kerala Health… Continue reading India is on alert after a fresh outbreak of the deadly Nipah virus. Here’s what you need to know

The Biden administration’s Medicare drug price negotiations, established under the Inflation Reduction Act, are nearing a significant milestone with negotiations for the first batch of drugs set to conclude soon. This landmark provision allows Medicare to directly negotiate prices for medications for the first time in its history, aiming to make costly drugs more affordable… Continue reading Healthy Returns: The first round of Medicare drug price negotiations is nearing an end

Pfizer announced on Wednesday that its experimental gene therapy for hemophilia A has achieved success in a large late-stage clinical trial, positioning it for potential approval. This treatment targets a rare genetic blood-clotting disorder, hemophilia A, which is caused by a deficiency in the blood-clotting protein factor VIII. If approved, it would be Pfizer’s second… Continue reading Pfizer’s gene therapy for rare genetic bleeding disorder succeeds in late-stage trial

Vancouver, British Columbia–(Newsfile Corp. – July 23, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce a strategic supply partnership and Letter of Intent with PsiloThai, a leading patient advocacy group… Continue reading Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

VANCOUVER, BC, July 23, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced that the United States Patent and Trademark Office (“USPTO”) has issued BioVaxys U.S. Patent No. 12,042,537. (“Patent”) for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. This… Continue reading BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE